MNPR MONOPAR THERAPEUTICS Earnings Reports 8-K Filing 2023 - Press Release Monopar Therapeutics plans to report interim analysis for Validive trial, clinical data from camsirubicin trial, and preclinical progress update on MNPR-101 RIT program.Get access to all SEC 8-K filings of the MONOPAR THERAPEUTICS